IgM myeloma: A multicenter retrospective study of 134 patients

J 2017

IgM myeloma: A multicenter retrospective study of 134 patients

CASTILLO, J.J.; A. JURCZYSZYN; Lucie BROŽOVÁ; E. CRUSOE; J. CZEPIEL et. al.

Základní údaje

Originální název

IgM myeloma: A multicenter retrospective study of 134 patients

Autoři

Vydání

American Journal of Hematology, Hoboken, Wiley, 2017, 0361-8609

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 5.303

Kód RIV

RIV/00216224:14110/17:00098291

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1002/ajh.24753

UT WoS

000405417100344

EID Scopus

2-s2.0-85019759763

Klíčová slova anglicky

IgM myeloma

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 21. 3. 2018 17:47, Soňa Böhmová

Anotace

V originále

IgM myeloma is a rare hematologic malignancy for which the clinicopathological features and patient outcomes have not been extensively studied. We carried out a multicenter retrospective study in patients with diagnosis of IgM myeloma defined by >10% marrow involvement by monoclonal plasma cells, presence of an IgM monoclonal paraproteinemia of any size, and anemia, renal dysfunction, hypercalcemia, lytic lesions and/or t(11;14) identified by FISH. A total of 134 patients from 20 centers were included in this analysis. The median age at diagnosis was 65.5 years with a male predominance (68%). Anemia, renal dysfunction, elevated calcium and skeletal lytic lesions were found in 37, 43, 19, and 70%, respectively. The median serum IgM level was 2,895 mgdL(-1) with 19% of patients presenting with levels >6,000 mgdL(-1). International Staging System (ISS) stages 1, 2, and 3 were seen in 40 (33%), 54 (44%), and 29 (24%) of patients, respectively. The malignant cells expressed CD20 (58%) and cyclin D1 (67%), and t(11;14) was the most common cytogenetic finding (39%). The median overall survival (OS) was 61 months. Higher ISS score was associated with worse survival (P=0.02). Patients with IgM myeloma present with similar characteristics and outcomes as patients with more common myeloma subtypes.

Citovat

CASTILLO, J.J.; A. JURCZYSZYN; Lucie BROŽOVÁ; E. CRUSOE; J. CZEPIEL; J. DAVILA; A. DISPENZIERI; M. EVEILLARD; M.A. FIALA; I.M. GHOBRIAL; A. GOZZETTI; J.N. GUSTINE; R. HAJEK; V. HUNGRIA; Jiří JARKOVSKÝ; D. JAYABALAN; J.P. LAUBACH; B. LEWICKA; V. MAISNAR; E.E. MANASANCH; P. MOREAU; E.A. MORGAN; H. NAHI; R. NIESVIZKY; C. PABA-PRADA; T. PIKA; Luděk POUR; J.L. REAGAN; P.G. RICHARDSON; J. SHAH; I. SPICKA; R. VIJ; A. WASZCZUK-GAJDA a M.A. GERTZ. IgM myeloma: A multicenter retrospective study of 134 patients. American Journal of Hematology. Hoboken: Wiley, 2017, roč. 92, č. 8, s. 746-751. ISSN 0361-8609. Dostupné z: https://doi.org/10.1002/ajh.24753.

@article{1395624,
   author = {Castillo, J.J. and Jurczyszyn, A. and Brožová, Lucie and Crusoe, E. and Czepiel, J. and Davila, J. and Dispenzieri, A. and Eveillard, M. and Fiala, M.A. and Ghobrial, I.M. and Gozzetti, A. and Gustine, J.N. and Hajek, R. and Hungria, V. and Jarkovský, Jiří and Jayabalan, D. and Laubach, J.P. and Lewicka, B. and Maisnar, V. and Manasanch, E.E. and Moreau, P. and Morgan, E.A. and Nahi, H. and Niesvizky, R. and PabaandPrada, C. and Pika, T. and Pour, Luděk and Reagan, J.L. and Richardson, P.G. and Shah, J. and Spicka, I. and Vij, R. and WaszczukandGajda, A. and Gertz, M.A.},
   article_location = {Hoboken},
   article_number = {8},
   doi = {https://doi.org/10.1002/ajh.24753},
   keywords = {IgM myeloma},
   language = {eng},
   issn = {0361-8609},
   journal = {American Journal of Hematology},
   title = {IgM myeloma: A multicenter retrospective study of 134 patients},
   volume = {92},
   year = {2017}
}

TY  - JOUR
ID  - 1395624
AU  - Castillo, J.J. - Jurczyszyn, A. - Brožová, Lucie - Crusoe, E. - Czepiel, J. - Davila, J. - Dispenzieri, A. - Eveillard, M. - Fiala, M.A. - Ghobrial, I.M. - Gozzetti, A. - Gustine, J.N. - Hajek, R. - Hungria, V. - Jarkovský, Jiří - Jayabalan, D. - Laubach, J.P. - Lewicka, B. - Maisnar, V. - Manasanch, E.E. - Moreau, P. - Morgan, E.A. - Nahi, H. - Niesvizky, R. - Paba-Prada, C. - Pika, T. - Pour, Luděk - Reagan, J.L. - Richardson, P.G. - Shah, J. - Spicka, I. - Vij, R. - Waszczuk-Gajda, A. - Gertz, M.A.
PY  - 2017
TI  - IgM myeloma: A multicenter retrospective study of 134 patients
JF  - American Journal of Hematology
VL  - 92
IS  - 8
SP  - 746-751
EP  - 746-751
PB  - Wiley
SN  - 03618609
KW  - IgM myeloma
N2  - IgM myeloma is a rare hematologic malignancy for which the clinicopathological features and patient outcomes have not been extensively studied. We carried out a multicenter retrospective study in patients with diagnosis of IgM myeloma defined by >10% marrow involvement by monoclonal plasma cells, presence of an IgM monoclonal paraproteinemia of any size, and anemia, renal dysfunction, hypercalcemia, lytic lesions and/or t(11;14) identified by FISH. A total of 134 patients from 20 centers were included in this analysis. The median age at diagnosis was 65.5 years with a male predominance (68%). Anemia, renal dysfunction, elevated calcium and skeletal lytic lesions were found in 37, 43, 19, and 70%, respectively. The median serum IgM level was 2,895 mgdL(-1) with 19% of patients presenting with levels >6,000 mgdL(-1). International Staging System (ISS) stages 1, 2, and 3 were seen in 40 (33%), 54 (44%), and 29 (24%) of patients, respectively. The malignant cells expressed CD20 (58%) and cyclin D1 (67%), and t(11;14) was the most common cytogenetic finding (39%). The median overall survival (OS) was 61 months. Higher ISS score was associated with worse survival (P=0.02). Patients with IgM myeloma present with similar characteristics and outcomes as patients with more common myeloma subtypes.
ER  -

CASTILLO, J.J.; A. JURCZYSZYN; Lucie BROŽOVÁ; E. CRUSOE; J. CZEPIEL; J. DAVILA; A. DISPENZIERI; M. EVEILLARD; M.A. FIALA; I.M. GHOBRIAL; A. GOZZETTI; J.N. GUSTINE; R. HAJEK; V. HUNGRIA; Jiří JARKOVSKÝ; D. JAYABALAN; J.P. LAUBACH; B. LEWICKA; V. MAISNAR; E.E. MANASANCH; P. MOREAU; E.A. MORGAN; H. NAHI; R. NIESVIZKY; C. PABA-PRADA; T. PIKA; Luděk POUR; J.L. REAGAN; P.G. RICHARDSON; J. SHAH; I. SPICKA; R. VIJ; A. WASZCZUK-GAJDA a M.A. GERTZ. IgM myeloma: A multicenter retrospective study of 134 patients. \textit{American Journal of Hematology}. Hoboken: Wiley, 2017, roč.~92, č.~8, s.~746-751. ISSN~0361-8609. Dostupné z: https://doi.org/10.1002/ajh.24753.

Přehled o publikaci